Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have received an average rating of “Moderate Buy” from the thirteen ratings firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, eleven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $10.6667.

TSHA has been the topic of a number of research analyst reports. Chardan Capital restated a “buy” rating and issued a $12.00 price target on shares of Taysha Gene Therapies in a report on Tuesday, January 6th. Wall Street Zen cut shares of Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, January 3rd. JMP Securities set a $8.00 target price on shares of Taysha Gene Therapies in a research report on Wednesday, November 5th. Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 price target on shares of Taysha Gene Therapies in a research note on Friday, October 17th. Finally, Citizens Jmp increased their price objective on Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “market outperform” rating in a research note on Wednesday, November 5th.

Taysha Gene Therapies Price Performance

Shares of TSHA stock opened at $4.41 on Friday. The stock has a 50 day moving average price of $5.11 and a 200 day moving average price of $4.16. Taysha Gene Therapies has a 52-week low of $1.05 and a 52-week high of $6.02. The company has a debt-to-equity ratio of 0.23, a quick ratio of 10.48 and a current ratio of 10.48. The firm has a market capitalization of $1.21 billion, a P/E ratio of -13.36 and a beta of 1.01.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.09) EPS for the quarter, meeting the consensus estimate of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%. As a group, sell-side analysts predict that Taysha Gene Therapies will post -0.35 earnings per share for the current year.

Insider Activity

In related news, CEO Sean P. Nolan sold 136,789 shares of Taysha Gene Therapies stock in a transaction dated Friday, January 23rd. The stock was sold at an average price of $4.75, for a total value of $649,747.75. Following the completion of the sale, the chief executive officer directly owned 2,949,569 shares in the company, valued at $14,010,452.75. The trade was a 4.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Sukumar Nagendran sold 260,047 shares of the business’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $4.51, for a total transaction of $1,172,811.97. Following the completion of the sale, the insider owned 1,006,439 shares of the company’s stock, valued at approximately $4,539,039.89. This represents a 20.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 967,140 shares of company stock worth $4,510,613. Company insiders own 3.78% of the company’s stock.

Institutional Trading of Taysha Gene Therapies

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. raised its position in shares of Taysha Gene Therapies by 3.3% in the 4th quarter. Vanguard Group Inc. now owns 13,267,805 shares of the company’s stock worth $72,973,000 after acquiring an additional 418,192 shares in the last quarter. Octagon Capital Advisors LP raised its holdings in Taysha Gene Therapies by 17.7% in the second quarter. Octagon Capital Advisors LP now owns 12,592,500 shares of the company’s stock worth $29,089,000 after purchasing an additional 1,892,500 shares in the last quarter. Jefferies Financial Group Inc. raised its holdings in Taysha Gene Therapies by 4,105.3% in the second quarter. Jefferies Financial Group Inc. now owns 10,313,733 shares of the company’s stock worth $23,825,000 after purchasing an additional 10,068,479 shares in the last quarter. Vestal Point Capital LP lifted its position in shares of Taysha Gene Therapies by 83.3% during the third quarter. Vestal Point Capital LP now owns 5,500,000 shares of the company’s stock valued at $17,985,000 after buying an additional 2,500,000 shares during the last quarter. Finally, Polar Capital Holdings Plc boosted its holdings in shares of Taysha Gene Therapies by 5.9% in the 3rd quarter. Polar Capital Holdings Plc now owns 5,293,879 shares of the company’s stock valued at $17,311,000 after buying an additional 293,879 shares in the last quarter. Institutional investors own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.